Abstracts Archive - Page 1466 of 2425 - ACR Meeting Abstracts

Abstract Number: 724 • 2016 ACR/ARHP Annual Meeting
Diminished Spinal Radiographic Progression during Long-Term Treatment with TNF-α Inhibitors in Ankylosing Spondylitis Patients at Risk of Poor Radiographic Outcome
Fiona Maas¹, Suzanne Arends^1,2, Freke Wink², Reinhard Bos², Hendrika Bootsma³, Elisabeth Brouwer¹ and Anneke Spoorenberg^1,2, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: In AS, spinal radiographic progression shows a very heterogeneous course. Our aim was to investigate which patient characteristics are of influence on the…
Abstract Number: 725 • 2016 ACR/ARHP Annual Meeting
Long-Term Anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in the Sacroiliac Joints in Patients with Non-Radiographic Axial Spa: Six-Year Results of the Esther Trial
Valeria Rios Rodriguez¹, Joachim Sieper¹, Kay-Geert Hermann², Hildrun Haibel¹, Christian Althoff², Beate Buß¹, Olaf Behmer³ and Denis Poddubnyy¹, ¹Rheumatology, Charité Universitätmeidzin Berlin, Berlin, Germany, ²Radiology, Charité Universitätmeidzin Berlin, Berlin, Germany, ³Pfizer Pharma, Berlin, Germany
Background/Purpose: Data from observational studies suggests a 10-12% biannual rate of progression from non-radiographic axial SpA (nr-axSpA) to ankylosing spondylitis (AS)1 in patients not treated…
Abstract Number: 726 • 2016 ACR/ARHP Annual Meeting
Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
Marianne Guirgis¹, Melanie Favre dit Jeanfavre², Charles Benaim³, Matthieu Perreau⁴, Pierre Michetti⁵, Michel Maillard¹ and Pascal Zufferey⁶, ¹gastroenterology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, MPR, Lausanne, Switzerland, ⁴Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁵La Source-Beaulieu, Lausanne, Switzerland, ⁶Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland
Background/Purpose: Infliximab is a biological agent frequently used for inflammatory arthritis (IA) such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis as well as for the inflammatory…
Abstract Number: 727 • 2016 ACR/ARHP Annual Meeting
Effects of Nsaids on Disease Activity in Ankylosing Spondylitis
Mark Hwang¹, Prabha Ranganathan², MinJae Lee³, Seth Eisen¹, Michael Ward⁴, Lianne S. Gensler⁵, Matthew A. Brown⁶, Johnathan Jia⁷, Amirali Tahanan³, Mohammad H. Rahbar³, Michael Weisman⁸ and John D. Reveille⁹, ¹Internal Medicine-Rheumatology, Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴NIH/NIAMS, Bethesda, MD, ⁵Medicine/Rheumatology, UCSF, San Francisco, CA, ⁶University of Queensland Diamantina Institute, Brisbane, Australia, ⁷University of Texas-McGovern Medical School, Houston, TX, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: NSAIDs are the first line pharmacologic therapy in ankylosing spondylitis (AS). Several NSAIDs are efficacious in AS without superiority demonstrated by any particular…
Abstract Number: 728 • 2016 ACR/ARHP Annual Meeting
Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Zheng Zhao, Gang Wang, Yanyan Wang, Jinshui Yang, Jian Zhu and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose : Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions,…
Abstract Number: 729 • 2016 ACR/ARHP Annual Meeting
Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?
Zineb Ez-Zaitouni¹, Pauline Bakker¹, Miranda van Lunteren¹, Inger Jorid Berg², Robert Landewé³, Maikel van Oosterhout⁴, Mariagrazia Lorenzin⁵, Désirée van der Heijde¹ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy
Background/Purpose: The number of clinical spondyloarthritis (SpA)-features plays an important role in the Assessment of SpondyloArthritis international Society (ASAS) modified Berlin algorithm for the diagnostic…
Abstract Number: 730 • 2016 ACR/ARHP Annual Meeting
Clinical and Quality of Life Improvements Observed with Golimumab and Infliximab in a Large Real-Life Ankylosing Spondylitis Population
Filip van Den Bosch¹, Rene-Marc Flipo², Jürgen Braun³, Shiva Sajjan⁴, N Vastesaeger⁵, Sumesh Kachroo⁶ and Marinella Govoni⁷, ¹Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Rheumatology, University Hospital, Lille, France, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵Merck Sharp & Dohme, Belgium, Brussels, Belgium, ⁶CORE, Merck & Co., Inc., Kenilworth, NJ, ⁷Via Tasso 14, Merck Sharp & Dohme, Italy, Cento, Italy
Background/Purpose : We assessed baseline parameters associated with health-related quality-of-life (HRQoL) improvement in AS patients with anti-TNF treatment (golimumab [GLM]; infliximab [IFX; originator]) in the…
Abstract Number: 731 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Maria Konsta¹, Michael Nurmohamed², J.C. van Denderen³, Ingrid Visman⁴ and I.E. Van der Horst - Bruinsma⁵, ¹Amsterdam Rheumatology and Immunology Center,VUmc and Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ³Center for Rheumatology and Rehabilitation, Jan van Breemen Institute, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and Immunology Center, VUmc and Reade, Amsterdam, Netherlands, ⁵GENRA Consortium, Amsterdam, Netherlands
Background/Purpose: Hip involvement is the most frequent extraspinal arthritic manifestation of Ankylosing Spondylitis (AS) and a common cause of disability. It is present in 24%…
Abstract Number: 732 • 2016 ACR/ARHP Annual Meeting
Long-Term Effect of TNF Inhibitors on Radiographic Progression in Ankylosing Spondylitis Is Associated with Syndesmophytes at Baseline and Time-Averaged CRP Levels
Maria Konsta^1,2, Grigorios Sakellariou³, Alexios Iliopoulos⁴, PETROS P SFIKAKIS⁵ and I.E. Van der Horst - Bruinsma⁶, ¹Amsterdam Rheumatology and Immunology Center,VUmc and Reade, Amsterdam, Netherlands, ²First Department of Propaedeutic and Internal Medicine, Laikon Hospital, Athens University Medical School, Greece, Athens, Greece, ³Rheumatology, Veterans Administration Hospital, Athens, Greece, ⁴Department of Rheumatology, Veterans Administration Hospital, Athens, Greece, ⁵First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁶GENRA Consortium, Amsterdam, Netherlands
Background/Purpose: Although the radiographic progression in AS is associated with both baseline and time-averaged level of CRP in TNF naïve patients, the effect of level…
Abstract Number: 733 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Andrea Regel¹, Alexandre Sepriano², Xenofon Baraliakos¹, Désirée van der Heijde², Juergen Braun¹, Robert Landewé³, Filip van Den Bosch⁴ and Sofia Ramiro², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: As part of the 2016 update of the ASAS/EULAR recommendations for the management of axSpA, we performed a systematic literature review (SLR) to assess…
Abstract Number: 734 • 2016 ACR/ARHP Annual Meeting
Lateral Spine BMD Measurement and Trabecular Bone Score Can Represent a Bone Loss in Patients with Advanced Ankylosing Spondylitis
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Sung-Hwan Park⁵ and Ji Hyeon Ju⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: It is well known that osteoporosis is paradoxically common in patients with ankylosing spondylitis (AS) in spite of their new bone formation and extraosseous…
Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis
Joachim Sieper¹, Atul A. Deodhar², Maja Hojnik³, Ying Zhang⁴ and Maxime Dougados⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Oregon Health and Science University, Portland, OR, ³AbbVie, Ljubljana, Slovenia, ⁴AbbVie, North Chicago, IL, ⁵René Descartes University and Hôpital Cochin, Paris, France
Background/Purpose: Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…
Abstract Number: 736 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Jieruo Gu¹, Liudan Tu², Minjing Zhao³, Zhiming Lin⁴, Zetao Liao⁵, Shuangyan Cao⁶, Qinghong Yu⁷ and Zhizhong Ye⁸, ¹Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ²The Third Hospital of Sun Yat-sen University, Guangzhou, China, ³The Third Affiliated Hospital of Sun Yat-sen University, guangzhou, China, ⁴Rheumatology, 3rd Affiliated Hospital of Sun Yat-Sen Uni, Guangzhou, China, ⁵Rheumatology, 3rd Affiliated Hoapital of Sun Yat-Sen Uni, Guangzhou, China, ⁶Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁷Department of Rheumatology, Fourth People’s Hospital of Shenzhen City, Xiangmi Lake branch, Guangzhou, China, ⁸Department of Rheumatology，ZhuJiang Hospital of Southern Medical University, Guangzhou, China
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment，and to evaluate the effectiveness…
Abstract Number: 737 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy
Michelle Petri¹, Wei Fu² and Syed Mahmood Shah³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The American Academy of Ophthalmology guidelines on hydroxychloroquine retinopathy were recently revised (Ophthalmology 2016;1-9). These guidelines recommend optical coherence tomography (OCT) with multifocal electroretinogram…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].